Core Viewpoint - The study highlights the critical role of mature tertiary lymphoid structures (mTLS) in mediating B cell-driven antitumor immunity in locally advanced rectal cancer (LARC) and discusses the detrimental effects of neoadjuvant therapy (neoTx) on mTLS [4][8]. Group 1: Research Findings - The research team conducted a multi-omics analysis on 161 LARC patient samples from two clinical centers, identifying mTLS and immature TLS (iTLS) through various techniques [6]. - mTLS tumors exhibited significant enrichment of B cells and plasma cells compared to iTLS, with bulk RNA sequencing revealing upregulation of plasma cell and follicular B cell-related gene signatures [6]. - Single-cell RNA sequencing indicated that plasma cells in mTLS not only had a higher proportion but also demonstrated greater clonal diversity and stronger immunoglobulin production capabilities, particularly for IgG and IgA [6]. Group 2: Clinical Implications - The presence of mTLS and high expression of plasma cell marker CD138 were significantly associated with longer overall survival (OS) in patients, suggesting that mTLS and B cell immunity are favorable prognostic markers in rectal cancer [7]. - Analysis of 125 patients undergoing neoTx revealed that while T cell infiltration increased, the proportion of mTLS significantly decreased, indicating that neoTx primarily activates T cell-mediated immunity at the expense of mTLS structures [8]. - In patients who did not respond to neoTx, B cell-related gene signatures and CD20⁺ B cell infiltration were significantly higher despite no increase in mTLS, suggesting a compensatory B cell immune response independent of mTLS, which may relate to treatment resistance [8]. Group 3: Future Directions - The findings underscore the importance of mTLS in the tumor microenvironment of rectal cancer and the complex remodeling effects of standard neoTx on immune responses [8]. - These insights provide a theoretical basis and potential biomarkers for developing new treatment strategies aimed at preserving or leveraging B cell immunity, particularly in conjunction with neoTx [8].

Core Viewpoint - Immune checkpoint blockade therapy has significantly changed the landscape of cancer treatment, showing strong efficacy in various cancer types, but the reasons for differential responses among patients remain unclear [1][3]. Group 1: Research Findings - A recent study published in Nature reveals that autoantibodies (AAb), typically associated with autoimmune diseases, can influence the response of cancer patients to immune checkpoint blockade therapy [3][5]. - The research involved 374 cancer patients receiving immune checkpoint blockade therapy and 131 healthy controls, mapping the immune response to 6172 extracellular and secreted proteins [5]. - The study identified approximately 3000 unique autoantibody responses in cancer patients, indicating a diverse "autoantibody response group" that has not yet reached saturation [7]. Group 2: Clinical Implications - Patients with interferon-targeting antibodies have a 40-fold higher probability of responding to treatment, contrasting with COVID-19, where similar antibodies increase mortality risk by 20-200 times [7]. - The findings suggest that targeting the exoproteome with specific autoantibodies could enhance the efficacy of immune checkpoint blockade therapy, leading to the potential development of drugs that mimic beneficial autoantibodies or neutralize harmful ones [9]. - The study also highlights that anti-TL1A antibodies enhance treatment effects by preventing T-cell apoptosis in the tumor microenvironment [12]. Group 3: Future Directions - The research opens new avenues for optimizing cancer immunotherapy by leveraging the role of autoantibodies in treatment responses, providing new targets and strategies for improving patient outcomes [9].